Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

The Effect of Smoking on Salivary and Serum Lipidomic Profiles in Patients With Periodontitis

11 listopada 2026 zaktualizowane przez: Nihan AKDOĞAN, Ankara University

This observational study aims to investigate how smoking and periodontal health affect lipid profiles in saliva and blood serum. Periodontitis is a chronic inflammatory disease that affects the tissues supporting the teeth, while smoking is an important risk factor for periodontal disease.

The study will include 56 adults divided into four groups according to their periodontal health and smoking status: non-smokers with periodontitis, smokers with periodontitis, periodontally healthy non-smokers, and periodontally healthy smokers.

Saliva and blood samples will be collected from each participant. Lipid profiles will be analyzed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS). The study will examine the individual and combined associations of periodontitis and smoking with lipid profiles and explore the relationship between lipid patterns in saliva and serum.

The findings may help identify lipid-related changes associated with periodontal disease and smoking and improve our understanding of their effects on oral and systemic health.

Przegląd badań

Status

Rekrutacyjny

Warunki

Interwencja / Leczenie

Szczegółowy opis

Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth-supporting tissues. Smoking is a major modifiable risk factor that influences periodontal inflammation, host immune responses, and disease progression. Both periodontitis and smoking may alter lipid metabolism and contribute to oxidative stress and inflammatory processes.

Lipidomics provides a comprehensive approach to investigating lipid species and metabolic alterations associated with disease. Saliva is a non-invasive biological fluid that may reflect both local oral conditions and systemic biological processes. Comparing salivary and serum lipidomic profiles may provide further insight into the metabolic changes associated with periodontal disease and smoking.

This observational, cross-sectional study will enroll 56 adults aged 18-65 years. Participants will be categorized into four groups based on periodontal status and smoking habits: periodontitis with smoking, periodontitis without smoking, periodontal health with smoking, and periodontal health without smoking.

Periodontal status will be determined through clinical periodontal examination. Saliva and blood samples will be obtained from the same participants, and untargeted lipidomic profiling will be performed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS).

The study will assess the associations of periodontal status and smoking with salivary and serum lipidomic profiles, including their potential interaction. Relationships between lipidomic patterns in the two biological fluids will also be investigated.

This study is expected to contribute to a better understanding of lipid-related biological alterations associated with periodontitis and smoking and may support future research into potential biomarkers of periodontal disease.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

56

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Ankara
      • Ankara, Ankara, Turcja (Türkiye), 06560
        • Rekrutacyjny
        • Ankara University Faculty of Dentistry
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

The study population will consist of 56 adults aged 18-65 years, categorized into four groups according to periodontal status and cigarette smoking: (1) patients with periodontitis who smoke, (2) patients with periodontitis who do not smoke, (3) periodontally healthy individuals who smoke, and (4) periodontally healthy individuals who do not smoke. Participants will be evaluated through clinical periodontal examinations, and saliva and serum samples will be collected for lipidomic profiling. All participants must meet the predefined eligibility criteria.

Opis

Inclusion Criteria:

Individuals aged 18 years or older. Individuals who do not use orthodontic appliances Women who are not pregnant or breastfeeding. Individuals without systemic diseases that may affect periodontal health. Individuals who have not used anti-inflammatory and/or antimicrobial medications within the past 6 months.

Individuals who have not received periodontal treatment within the past year.

Exclusion Criteria:

Individuals younger than 18 years. Individuals older than 65 years. Pregnant or breastfeeding women. Individuals who have used anti-inflammatory and/or antimicrobial medications within the past 6 months.

Individuals who have received periodontal treatment within the past year. Individuals with psychiatric disorders. Individuals with any oral infection. Individuals with alcohol dependence. Individuals with active infectious diseases (acute hepatitis, AIDS, or tuberculosis), cancer, or any systemic disease that may affect periodontal tissues.

Individuals receiving medications known to affect periodontal tissues, including phenytoin, cyclosporine A, or calcium channel blockers.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: CROSS_SECTIONAL

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Periodontitis Smokers

Adult participants diagnosed with periodontitis who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

Periodontitis Non-Smokers

Adult participants diagnosed with periodontitis who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

Periodontally Healthy Smokers

Adult participants with clinically healthy periodontal tissues who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

Periodontally Healthy Non-Smokers

Adult participants with clinically healthy periodontal tissues who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling.

Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered.

Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity.

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity.

Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation.

Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Salivary Lipidomic Profile
Ramy czasowe: At baseline (single sample collection)

Salivary lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status.

At baseline (single sample collection)
Serum Lipidomic Profile
Ramy czasowe: At baseline (single sample collection)

Serum lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status.

At baseline (single sample collection)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Probing Pocket Depth (PPD)
Ramy czasowe: At baseline (single clinical examination)

Probing pocket depth (PPD) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean PPD values will be calculated to characterize periodontal status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)
Attachment Loss (AL)
Ramy czasowe: At baseline (single clinical examination)

Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean AL values will be calculated to characterize periodontal tissue destruction, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)
Bleeding on Probing (BOP)
Ramy czasowe: At baseline (single clinical examination)

Bleeding on probing (BOP) will be assessed at six sites per tooth. The percentage of sites exhibiting bleeding will be calculated to characterize gingival inflammation, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)
Plaque Index (PI)
Ramy czasowe: At baseline (single clinical examination)

Plaque index (PI) will be assessed to quantify dental plaque accumulation. Individual plaque index scores will be calculated according to the study protocol to characterize oral hygiene status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles.

At baseline (single clinical examination)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

11 listopada 2026

Zakończenie podstawowe (Szacowany)

31 grudnia 2026

Ukończenie studiów (Szacowany)

31 grudnia 2026

Daty rejestracji na studia

Pierwszy przesłany

11 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 listopada 2026

Pierwszy wysłany (Rzeczywisty)

17 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant data (IPD) will not be shared with other researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form through scientific publications without disclosing identifiable participant information.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .